Assembly Biosciences announced that its Chief Medical Officer, Anuj Gaggar, MD, PhD, will present at the Bank of America Securities 2026 Global Health Care Conference on May 13, 2026. The company also highlighted positive Phase 1b data for its helicase-primase inhibitors ABI-5366 and ABI-1179 for recurrent genital herpes treatment, with additional data selected for oral presentation and late-breaker poster presentation at ESCMID Global 2026.

Assembly Biosciences reported Q1 2026 financial results with cash reserves of $226.6 million, sufficient to fund operations into 2028. The company completed Phase 1b studies for herpes candidates ABI-5366 and ABI-1179 (licensed to Gilead) and chronic toxicology studies for hepatitis delta virus candidate ABI-6250, with Phase 2 initiation expected in Q4 2026. Net loss was $9.1 million for the quarter.

Assembly's NeosAI, built on Microsoft Azure AI Foundry, has demonstrated significant time savings and workflow automation for law firms, with advanced natural language processing and enterprise-grade security.

Insiders have been purchasing shares in American Software, Assembly Biosciences, and Tile Shop Holdings, indicating their confidence in the companies' prospects.

– Phase 1a study portion of single ascending dosing in healthy participants will inform the development of ABI-5366 with interim data expected in Q3 2024 –

Here is how Entera Bio Ltd. (ENTX) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.

Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.

SOUTH SAN FRANCISCO, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results and recent highlights for the fourth quarter and year ended December 31, 2023.

Shares of Icosavax, Inc. (NASDAQ: ICVX) rose sharply in pre-market trading after AstraZeneca announced plans to buy Icosavax in a deal valued at up to $1.1 billion. Icosavax also reported topline interim Phase 2 results for combination VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults. Icosavax shares gained 44.8% to $15.19 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Bruush Oral Care Inc. (NASDAQ: BRSH) shares rose 76.8% to $0.2882 in pre-market trading after gaining over 5% on Monday. Connect Biopharma Holdings Limited (NASDAQ: CNTB) rose 32.2% to $1.19 in pre-market trading. Connect Biopharma will present top-line data from the global Phase 2b trial evaluating rademikibart’s efficacy and safety in patients with moderate-to-severe asthma on Dec. 12, 2023. Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) shares rose 28% to $0.3159 in pre-market trading. Kaival Brands recently appointed James W. Dobbins as General Counsel. IN8bio, Inc.(NASDAQ: INAB) gained ...

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced a grant of inducement awards to its chief medical officer, Anuj Gaggar, MD, PhD on November 8, 2023.

U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite falling around 50 points on Tuesday. The Dow traded down 0.09% to 33,954.39 while the NASDAQ fell 0.37% to 13,517.59. The S&P 500 also fell, dropping, 0.10% to 4,369.41. Check This Out: Accenture, Robinhood And 2 Other Stocks Insiders Are Selling   Leading and Lagging Sectors   Materials shares climbed by 1% on Tuesday. In trading on Tuesday, information technology shares fell by 0.4%.   Top Headline   Bank of America Corp (NYSE: BAC) reported better-than-expected earnings for its third quarter on Tuesday. The bank said EPS for the quarter was $0.90, compared to $0.81 in the year-ago period, beating the consensus of $0.81. Revenue increased 3% year-over-year to $25.32 billion, beating the consensus of $25.14 billion.   Equities Trading UP   SciSparc Ltd. (NASDAQ: SPRC) shares shot up 122% to $6.28. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc. Shares of Assembly Biosciences, Inc. (NASDAQ: ASMB) got a boost, shooting 80% to $1.3101 after the company and Gilead announced they entered into a 12-year partnership to advance the research and development of novel ...

Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc. Assembly Biosciences, Inc. (NASDAQ: ASMB) gained 120% to $1.5982 after the company and Gilead announced they entered into a 12-year partnership to advance the research and development of novel antiviral therapies. Olink Holding AB (NASDAQ: OLK) shares climbed 65.8% to $24.84 after Thermo Fisher Scientific announced it will acquire the company. MoneyHero Limited (NASDAQ: MNY) surged 33.7% to $3.40. OpGen, Inc. (NASDAQ: OPGN) gained 32.7% to $1.20. FLJ Group Limited (NASDAQ: FLJ) jumped 29.3% to $0.2689. Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) gained 22.5% to $2.0950. Ramaco Resources, Inc. (NASDAQ: METC) rose 20.2% to $11.73. Aurora Mobile Limited (NASDAQ: JG) shares climbed 19.8% to $0.1593 after gaining 8% on Monday. Nkarta, Inc. (NASDAQ: NKTX) rose 18.5% to $1.75 as the company received FDA clearance of IND application for NKX019 in lupus nephritis. AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) gained 18% to $3.0905. Gamer Pakistan Inc. (NASDAQ: GPAK) gained 16.8% to $1.46. Summit Therapeutics Inc. (NASDAQ: SMMT) rose 16% to $2.03. Meiwu Technology Company Limited (NASDAQ: WNW) shares rose 15.4% to $0.1062 after falling 4% on Monday. WiSA Technologies, Inc. (NASDAQ: WISA) shares gained 12.8% to $0.28 after falling 40% on Monday. WiSA Technologies announced pricing of ...